Literature DB >> 19487261

Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis.

Khulood Mohammed1, Janet Pope, Nicole Le Riche, William Brintnell, Ewa Cairns, Robert Coles, David A Bell.   

Abstract

OBJECTIVE: To evaluate the clinical, serologic, and MHC class II antigen characteristics of a group of patients with primary Sjögren's syndrome (SS) and severe arthritis.
METHODS: A case-control study comparing 35 patients with primary SS: 17 with inflammatory arthritis, 18 without arthritis.
RESULTS: All patients fulfilled criteria for primary SS. There were no demographic or clinical features other than inflammatory arthritis, often erosive, that distinguished patients with arthritis from those without. All patients had anti-Ro/SSA autoantibodies, most had anti-La/SSB autoantibodies, and a high percentage of these patients had anti-citrullinated peptide antibodies absent in those without inflammatory arthritis. HLA typing revealed that most patients with anti-citrulline antibodies expressed MHC class II molecules with the shared epitope (SE). The presence of DRB1*0301 linked to the expression of anti-Ro/SSA autoantibodies did not influence the level or frequency of anti-citrulline antibodies in these patients.
CONCLUSION: Severe arthritis with features resembling rheumatoid arthritis including erosive disease can occur in primary SS, particularly among those with anti-citrulline antibodies and the SE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487261     DOI: 10.3899/jrheum.080234

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients.

Authors:  Thelma L Skare; Renato Nisihara; Bruno Bandolin Barbosa; Alvaro da Luz; Shirley Utiyama; Vanessa Picceli
Journal:  Clin Rheumatol       Date:  2013-02-15       Impact factor: 2.980

2.  Blocking IAg7 class II major histocompatibility complex by drug-like small molecules alleviated Sjögren's syndrome in NOD mice.

Authors:  Shivai Gupta; Danmeng Li; David A Ostrov; Cuong Q Nguyen
Journal:  Life Sci       Date:  2021-11-27       Impact factor: 5.037

3.  Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up.

Authors:  E J ter Borg; J C Kelder
Journal:  Clin Rheumatol       Date:  2016-01-20       Impact factor: 2.980

4.  Sjögren's syndrome.

Authors:  Fiona André; Barbara C Böckle
Journal:  J Dtsch Dermatol Ges       Date:  2022-07-01       Impact factor: 5.231

5.  Joint involvement in primary Sjögren's syndrome: an ultrasound "target area approach to arthritis".

Authors:  Luis M Amezcua-Guerra; Fritz Hofmann; Angelica Vargas; Pedro Rodriguez-Henriquez; Carla Solano; Cristina Hernández-Díaz; Diana Castillo-Martinez; Lucio Ventura-Ríos; Marwin Gutiérrez; Carlos Pineda
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.